Veru Shares Tumble Regardless of Enobosarm’s Lean Muscle Preservation Breakthrough – Veru (NASDAQ:VERU)

Veru Inc. VERU inventory is plummeting on Monday after the corporate launched topline outcomes from the Section 2b QUALITY scientific research of enobosarm for weight discount.

The research evaluates the protection and efficacy of enobosarm 3mg and enobosarm 6mg, in comparison with placebo in 168 older sufferers, better than 60 years of age, who’re chubby or have weight problems and who’re receiving Novo Nordisk A/S’ NVO Wegovy (semaglutide).

The first endpoint was the change in whole lean physique mass, and key secondary endpoints had been the change from baseline to 16 weeks in whole fats mass, whole physique weight, and bodily perform as measured by a stair climb check.

The research met its major endpoint with a statistically important profit in preservation of whole lean physique mass in all sufferers receiving enobosarm + semaglutide versus placebo + semaglutide at 16 weeks.

Secondary endpoints confirmed:

• On common, sufferers on Enobosarm + semaglutide therapy misplaced 71% much less lean mass than sufferers receiving Wegovy alone.
• Sufferers on Enobosarm + semaglutide therapy on common misplaced 27% extra fats mass than sufferers receiving Wegovy alone.
• There look like minor variations in whole physique weight modifications between the enobosarm+semaglutide group and placebo+semaglutide group at 16 weeks. Subsequently, enobosarm+semaglutide improved modifications in physique composition and resulted in additional selective and better fats mass loss than in topics receiving placebo + semaglutide.
• The proportion of topics who misplaced ≥10% stair climb energy was statistically important and clinically meaningfully diminished within the enobosarm + semaglutide teams in comparison with the placebo + semaglutide group.
• Subsequently, enobosarm diminished the proportion of sufferers who misplaced clinically important bodily perform in comparison with topics receiving semaglutide alone.

Additionally Learn: Veru Sells FC2 Condom Enterprise For $18 Million, Focuses On Biopharma Pipeline

Security knowledge stays blinded within the ongoing scientific research and the unblinded security set will probably be obtainable when the Section 2b extension research is completed in April 2025.

The Section 2b extension trial is ongoing wherein all sufferers cease receiving a GLP-1 RA however proceed taking a placebo, enobosarm 3mg or enobosarm 6mg, for a further 12 weeks.

The Section 2b extension research will consider the upkeep of weight reduction, that means whether or not enobosarm can preserve muscle and forestall the fats and weight acquire that happens after discontinuing a GLP-1 RA.

Value Motion: Veru inventory is down 48.5% at 62 cents final test Monday.

Learn Subsequent:

Picture: Shutterstock